Skip to main content

Advertisement

Table 2 Baseline characteristics of the participants in the TEAMcare for COPD pilot trial

From: Implementation challenges in delivering team-based care (‘TEAMcare’) for patients with chronic obstructive pulmonary disease in a public hospital setting: a mixed methods approach

Patients N = 12
Mean age (years) 64 (11)
Gender (female) 9/12 (75 %)
Education level (High school or less) 8/12 (67 %)
Smoking status
 Current smoker 2/12 (17 %)
 Former smoker 8/12 (67 %)
Moderate-Vigorous exercise (hours/week)a 2.5 (1.9)
Fruit serves/day (≥2) 6/12 (50 %)
Vegetable serves/day (≥4) 4/12 (33 %)
Unintentional weight loss (≥5 kg past 6 months) 2/12 (17 %)
Overweight (BMI 25–29.9) 3/12 (25 %)
Obese (BMI ≥30) 7/12 (58 %)
High waist circumference (≥102 cm men, ≥88 cm women) 9/12 (75 %)
High blood pressure (≥130/80 mmHg) 7/12 (58 %)
Mean FEV1% (SD) 58 (16)
Mean FVC% (SD) 90 (20)
Mean FEV1/FVC (SD) 0.53 (0.13)
Mean SpOb% 97 (1.7)
Inhaled medications
 LAMA 7/12 (58 %)
 LABA 9/12 (92 %)
 ICS 9/12 (92 %)
 SAMA 1/12 (8 %)
Cardiovascular medications 7/12 (58 %)
Diabetes medications 2/12 (17 %)
Other medications 7/12 (17 %)
Impairment (CAT score ≥10) 8/12 (67 %)
Breathlessness (mMRC score Grade ≥2) 4/12 (33 %)
Clinically relevant depression (PHQ-9 score ≥10) 1/12 (8 %)
Clinically relevant anxiety (GAD-7 score ≥10) 2/12 (17 %)
Clinically relevant somatic symptoms (PHQ-15 score ≥10) 3/12 (25 %)
Blood tests
 White cell count (x 10^9/L)b 9.0 (4.7)
 C-Reactive Protein (mg/L)b 8.5 (4.8)
 25-hydroxyvitamin D (<60 nmol/L) 7/8 (88 %)
  1. Legend: BMI body mass index, FEV1 forced expiratory volume in one second, FVC forced vital capacity, SpO 2 oxygen saturation estimate, LAMA long-acting antimuscarinic agent, LABA long-acting beta agonist, ICS inhaled corticosteroid, CAT COPD assessment test, mMRC modified Medical Research Council, PHQ patient health questionnaire, GAD general anxiety disorder
  2. a missing one observation; b missing four observations